ClinicalTrials.gg
Not yet recruitingNCT07618325Updated Jun 1, 2026

A Study to Evaluate the Immune Response Features Following Vaccination With a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

An interventional study of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Respiratory Syncytial Virus (RSV), sponsored by MAXVAX Biotechnology Limited Liability Company. Not yet recruiting. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by MAXVAX Biotechnology Limited Liability Company · Not applicable, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to elucidate the molecular mechanism by which novel adjuvants enhance the immunogenicity of Respiratory Syncytial Virus (RSV) vaccines by regulating antigen-specific B cell affinity maturation and T cell memory formation.

Read the detailed description

Novel adjuvants can effectively induce humoral immunity and generate neutralizing antibodies, as well as activate cellular immunity to clear intracellular pathogens.They mainly include particle-based adjuvants based on molecular agonists, synthetic inorganic/organic particulate materials, and virus-like particle mimetics.This study focuses on the mechanisms by which adjuvants enhance humoral and cellular immunity, analyzes antibody lineages, structural characteristics, and the patterns of T-cell activation, differentiation and memory formation, and elucidates the regulatory effects of adjuvants on antibody breadth and neutralizing activity. This study aims to systematically study the role of RSV adjuvants in enhancing high-affinity antibody responses and CD4⁺/CD8⁺ memory T cell generation through multi-dimensional immune analysis methods, including B Cell Receptor (BCR) / T Cell Receptor (TCR) sequencing, flow cytometry, and single-cell omics, so as to provide theoretical basis and new ideas for improving the sustainability and broad-spectrum immunization effect of novel RSV vaccines. A total of 60 adults aged 20 years and above will be enrolled. All participants will receive a single dose of investigational vaccine.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)
03

In context

Lead sponsor

MAXVAX Biotechnology Limited Liability Company is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 20 years of age or older as determined by the investigator at enrollment.
  • Participants must be able to understand study procedures, risks, and benefits, provide voluntary agreement to participate in the study, and sign the form (ICF).
  • Participants must be willing and able to attend all scheduled follow-up visits and comply with all requirements specified in the study protocol.
  • Females of must use highly effective from 1 month prior to vaccination through 12 months following vaccination.

    • Effective contraceptive methods include: oral contraceptives (excluding emergency contraceptives), contraceptive injections, subcutaneous implants, hormonal patches, intrauterine devices (IUDs), surgical sterilization, true abstinence, and condom use.
    • Methods not considered effective include: rhythm method, withdrawal method, and emergency contraception.

Exclusion criteria

Exclusion Criteria:

*Participants who meet any of the following criteria shall be ineligible for enrollment:

  • Axillary body temperature ≥ 37.3 °C.
  • History of respiratory syncytial virus (RSV) infection within 6 months prior to enrollment.
  • New-onset respiratory infection symptoms within 7 days prior to enrollment, including cough, expectoration, dyspnea, wheezing, fever, rhinorrhea, and nasal obstruction.
  • Presence of an acute illness or acute exacerbation of a chronic condition within 3 days prior to enrollment.
  • Use of antipyretics and analgesics (excluding enteric-coated aspirin for the prevention of cardiovascular and cerebrovascular diseases) or antiallergic medications within 3 days prior to enrollment.
  • Known to any ingredient of the study vaccine, including Quillaja saponaria (QS-21), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol, sucrose, sodium dihydrogen phosphate, anhydrous disodium hydrogen phosphate, polysorbate 80, sodium chloride, hydrochloric acid, and sodium hydroxide; history of severe allergic reactions or serious adverse events following any vaccination or drug administration, including anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local Arthus reaction, and severe urticaria.
  • Pregnant female (positive urine pregnancy test), lactating female, or female with a pregnancy plan within 12 months following vaccination.
  • Congenital asplenia, functional asplenia, or splenectomy due to any cause.
  • Previous or current malignant neoplasm, with the exception of clinically cured carcinoma in situ and papillary thyroid carcinoma.
  • Confirmed diagnosis of an disease, including systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, and autoimmune thyroid disease.
  • Confirmed or suspected or immunodeficiency resulting from any cause, including primary or secondary immunocompromise, congenital or acquired immunodeficiency, (HIV) infection, or treatment with immunosuppressive or cytotoxic agents (e.g., chemotherapy, organ transplantation, or therapy for autoimmune diseases).
  • Any condition that, in the investigator's judgment, would render intramuscular injection unsafe, such as a history of thrombocytopenia or other coagulation disorders.
  • Previous or current serious clinical illness that is not cured (such as serious cardiovascular and cerebrovascular diseases, liver and kidney diseases, respiratory diseases, diabetes with complications, major surgery, etc.) may affect the evaluation of the trial.
  • Previous or current thrombotic diseases.
  • History of untreated tuberculosis or active tuberculosis infection at enrollment.
  • Uncontrolled hypertension defined as systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg on measurement prior to vaccination.
  • History of severe cardiac arrhythmia (e.g., atrial fibrillation).
  • History or family history of convulsions, epilepsy, congenital brain malformation, psychiatric disorders, or other severe neurological conditions associated with cerebral nerve tissue injury, including brain tumor, cerebral hemorrhage, cerebral infarction (excluding lacunar cerebral infarction and cerebral infarction without sequelae), central nervous system infection, and chemical intoxication.
  • History of any cognitive disorder or any moderate or severe condition causing cognitive impairment.
  • Use of any or unlicensed product (medicinal product, vaccine, or medical device) other than the study vaccine within 30 days prior to vaccination, or planned participation in another clinical trial during the study period.
  • Administration of any inactivated vaccine within 14 days prior to vaccination, or any within 28 days prior to vaccination.
  • Prior receipt of any RSV vaccine.
  • Administration of immunoglobulin and/or any blood or plasma derivative (e.g., gamma globulin, intravenous immunoglobulin) within 3 months prior to vaccination, or planned administration during the study period.
  • Long-term use (consecutive use > 14 days) of immunosuppressive or other immunomodulatory agents within 3 months prior to vaccination or planned use during the study period. Systemic ≥ 20 mg prednisone or equivalent daily for ≥ 14 days are considered long-term use. Topical preparations (ointments, eye drops, inhalations, nasal sprays) at doses not exceeding those recommended in the package insert are permitted.
  • Use of long-acting immunomodulatory agents (e.g., infliximab) within 6 months prior to vaccination or planned use during the study period.
  • History of chronic alcohol abuse and/or drug abuse that, in the investigator's judgment, may interfere with study assessments.
  • Planned migration during the study period that would preclude completion of all study procedures.
  • Any other condition that, in the investigator's judgment, may interfere with the validity of study evaluations, with special attention to respiratory infection symptoms.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Vaccine Group

    Participants will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), by IM injection into the deltoid muscle of the upper arm.

    Biological: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

06

What researchers measure

Primary outcomes

  1. Neutralizing Antibodies against both the RSV-A and RSV-B subtypes.

    Measured by Virus Neutralization Test.

    Time frame: At pre-vaccination (Day 1), and at 1, 12, and 24 months post-vaccination.

  2. Specific IgG Antibodies to RSV pre-F of both RSV-A and RSV-B subtypes.

    Measured by ELISA.

    Time frame: At pre-vaccination (Day 1), and at 1 month, 12 months, and 24 months post-vaccination.

  3. The Frequency of RSV pre-F Specific Cluster of Differentiation 4+ (CD4+) T Cells or Cluster of Differentiation 8+ (CD8+) T cells Expressing.

    Among markers expressed were interleukin-2 (IL-2), cluster of 40 ligand (CD40L), tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSV-PreF peptide preparations. Measured by Intracellular Cytokine Staining (ICS).

    Time frame: At pre-vaccination (Day 1), and at 1 month, 12 months, and 24 months post-vaccination.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2026
First posted
Jun 1, 2026
StartEst.
Jun 2, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Aug 31, 2028
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07618325
Lead sponsor
MAXVAX Biotechnology Limited Liability Company
Collaborators
Henan Center for Disease Control and Prevention
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 2, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Jun 1, 2026

Study contacts

LiangHao Zhang
Contact
lianghao.zhang@maxvax.cn
+86 18971498772

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CHO cell

Start the discussion